Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met ...

Ryan Kessinger, Sr., 5-10, S, Jake Starr, Sr., 6-1, OH, Mario Romagni, Sr., 6-0, OH, Tony Masters, Sr., 6-5, MH, Maddox Fuenes, So., 6-5, MH, Levi Rohl, Sr., 5-11, OPP, Trent Hornak, Sr., 5-9, L ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

We recently published a list of 10 Firms Kick Off Trading Week Stronger. In this article, we are going to take a look at ...

As the guests of honor, they walked down a red carpet, free of kids for the night, to enjoy time with others in the community ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Tyler ISD Police Department arrested three employees on Friday. Dr. Marty Crawford said it did involve a student with ...